PolyPid (NASDAQ:PYPD) & NLS Pharmaceutics (NASDAQ:NCEL) Head-To-Head Survey

PolyPid (NASDAQ:PYPD) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.

Risk and Volatility

PolyPid has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500.

Institutional and Insider Ownership

26.5% of PolyPid shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for PolyPid and NLS Pharmaceutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1	0	5	0	2.67
NLS Pharmaceutics	1	0	0	0	1.00

PolyPid currently has a consensus target price of $12.25, suggesting a potential upside of 170.42%. Given PolyPid’s stronger consensus rating and higher probable upside, analysts clearly believe PolyPid is more favorable than NLS Pharmaceutics.

Valuation & Earnings

This table compares PolyPid and NLS Pharmaceutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17 million	($2.26)	-2.00
NLS Pharmaceutics	N/A	N/A	-$1.98 million	N/A	N/A

Profitability

This table compares PolyPid and NLS Pharmaceutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-291.42%	-131.82%
NLS Pharmaceutics	N/A	N/A	N/A

Summary

PolyPid beats NLS Pharmaceutics on 6 of the 9 factors compared between the two stocks.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

About NLS Pharmaceutics

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.